Toronto, Ontario – December 17, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that Health Canada has approved its next generation anti-cancer drug, TLD-1433, under Clinical Trial Application (“CTA”) for evaluation in a Phase Ib clinical trial for patients inflicted with Non-Muscle Invasive Bladder Cancer (“NMIBC”). Health Canada recently reviewed the CTA submitted by the Company and has issued a “No Objection Letter” stating that Health Canada has no objection to the proposed Phase Ib clinical study, a standard response, allowing the Company to proceed with enrolling patients who meet the inclusion and exclusion criteria of the study pending Health Canada Investigational Testing Authorization (“ITA”) of the TLC-3200 medical laser system used to activate TLD-1433 in the bladder and University Health Network Review Ethics Board (“UHN REB”) approval of the clinical … Read More

Toronto, Ontario – December 14, 2016, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT: TSXV) (TLTFF: OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that it has released the video presentations conducted at the end of its Annual General and Special Meeting held on December 9, 2016 in Toronto, Canada. The presentations were delivered by Dr. Lothar Lilge, Senior Scientist, Princess Margaret Cancer Center, University Health Network (“UHN”) and Dr. Girish Kulkarni, Uro-Oncologist, also from UHN. The video of the presentations may be viewed at: https://www.youtube.com/watch?v=uZuqltillSM&feature=youtu.be Roger Dumoulin-White, President and CEO of Theralase stated that, “Theralase has made significant advances in 2016 in both of its divisions. In the TLT division, Theralase has successfully commercialized its next generation TLC-2000 therapeutic laser system in both Canada and the US. In the … Read More

Toronto, Ontario – December 13, 2016 – Theralase Technologies Inc. (“Theralase” or the “Corporation”) (TLT: TSXV) (TLTFF: OTC) today announced that its board of directors (“Board“) has adopted By-Law No. 3 (“By-Law”) to establish a framework for the advance notice of nominations of directors by shareholders of Theralase (the “Advance Notice Requirement”). The purpose of the Advance Notice Requirement is to treat all shareholders fairly by ensuring that all shareholders, including those participating in a meeting by proxy rather than in person, receive adequate notice of the nominations to be considered at a meeting and sufficient information with respect to all nominees to enable them to exercise their voting rights in an informed manner. In addition, the Advance Notice Requirement should assist in facilitating an orderly and efficient meeting process. Among other things, the Advance Notice Requirement fixes a deadline by which shareholders must notify Theralase of nominations of persons … Read More

Toronto, Ontario – November 30, 2016, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that it has demonstrated 12 month long term stability of it lead anti-cancer Photo Dynamic Compound (“PDC”), TLD-1433. Stability studies are an essential component of pharmaceutical development, allowing evaluation of a drug’s stability under the influence of a variety of environmental factors such as: temperature, humidity and light. Data from these studies enable recommended storage conditions, retest intervals and shelf lives to be established. Demonstrating long term stability of a drug to be used in human clinical testing is essential to prove that the potency and/or efficacy of the drug is not affected during prolonged shelf life.   Under long term and accelerated stability storage conditions, the drug … Read More

Toronto, Ontario – November 29, 2016, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that for the nine-month period ended September 30, 2016, total revenue increased from $1,061,608 to $1,206,726 from the same period in 2015, a 14% increase. In Canada, revenue decreased 18% to $728,277 from $885,562. In the US, revenue increased 193% to $399,445 from $136,382 and international revenue increased 99% to $79,004 from $39,665. The decrease in Canadian revenue in 3Q2016 and the corresponding increase in US and international revenue is attributable to the Company systematically building its sales and marketing teams in the Canadian and US market and the learning curves associated with training and developing a new sales force. In December 2015, the next generation TLC-2000 laser … Read More

Not for distribution to U.S. news wire services or dissemination in the United States.  Toronto, Ontario – November 10, 2016 – Theralase Technologies Inc. (“Theralase” or the “Corporation”) (TSXV:TLT) (OTC Pink®: TLTFF) is pleased to announce that it has closed its previously announced public offering (the “Offering”) of units (each, a “Unit”). On closing, the Corporation issued an aggregate of 14,236,666 Units at a price of $0.30 per Unit for aggregate gross proceeds of approximately $4,271,000. Each Unit consists of one common share of the Corporation (each, a “Common Share”) and one common share purchase warrant (each, a “Warrant”). Each Warrant entitles the holder to acquire an additional Common Share at a price of $0.375 for a period of 60 months following the date of issuance. Echelon Wealth Partners Inc. (the “Agent”) acted as sole agent in connection with the Offering pursuant to the terms and conditions of an agency … Read More

Not for distribution to U.S. news wire services or dissemination in the United States.  Toronto, Ontario – November 7, 2016, Theralase Technologies Inc. (“Theralase” or the “Corporation”) (TSXV:TLT) (OTC Pink®: TLFF) is pleased to announce that it proposes to offer for sale up to 20,000,000 units of the Corporation (each, a “Unit”) at a price of $0.30 per Unit for aggregate gross proceeds of up to $6,000,000 (the “Offering”). Each Unit will consist of one common share of the Corporation (each, a “Common Share”) and one common share purchase warrant (each, a “Warrant”). Each Warrant will entitle the holder to acquire an additional Common Share (each a “Warrant Share”) at a price of $0.375 for a period of 60 months following the date of issuance. In connection with the Offering, the Corporation has engaged Echelon Wealth Partners Inc. (the “Agent”) to offer the Units for sale to the public on … Read More

Toronto, Ontario – November 3, 2016 – Theralase Technologies Inc. (“Theralase” or the “Corporation”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of photodynamic compounds to destroy cancer, announced today it is filing amended and restated financial statements (together with an amended corresponding management’s discussion and analysis) for the quarter ended June 30, 2016 (collectively, the “Amended Financial Report”) to correct the accounting errors identified below.   In the 2Q2016 financial statements, filed August 29,2016:   Prepaid expenses were overstated by $62,692. Finished Goods Inventory Overhead was overstated by $66,377. Accrued Liabilities were overstated by 62,763.   The net impact of the correction of the above stated items to the Balance Sheet is a:   reduction in Total Assets from $4,705,471 to $4,576,402, representing a net reduction of $129,069 (approximately 2.7%); and reduction in Total Liabilities from $419,457 to … Read More

Toronto, Ontario – November 1, 2016 – Theralase Technologies Inc. (“Theralase” or the “Corporation”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of photodynamic compounds  to destroy cancer, announced today that it wishes to provide clarification with respect to certain forward-looking information included in an interview with the Corporation’s President and Chief Executive Officer posted at www.smallcappower.com on February 18, 2016. Such forward-looking information included statements with respect to projected sales of up to $10 million for fiscal year 2016 as well as certain other long term projections. Such information constitutes forward-looking information within the meaning of National Instrument 51-102 – Continuous Disclosure and was subject to certain underlying assumptions including: Ability to ramp up manufacture of the TLC-2000 to commercial production levels; Ability to optimize the software for ease of use and functionality Ability to execute on a … Read More

Toronto, Ontario – October 28, 2016, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotech company focused on the commercialization of medical laser systems to eliminate pain and the development of light activated Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today an ability of its Photo Dynamic Therapy (“PDT”) technology to increase survival by 925% in a very aggressive form of brain cancer, known as Glioblastoma Multiforme (“GBM”). In an orthotopic rat model (GBM established in brain tissue), Theralase was able to demonstrate that the animal treated by the laser activated Theralase PDC Rutherrin® (TLD-1433 + transferrin) technology survived for a total of 41 days post treatment (37 days longer than untreated animals) resulting in a 925% survival increase. The current survival rate for untreated animals is approximately 4 days. The current median survival in humans without treatment is approximately 8.1 months or 0.7 years1. The … Read More